Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Thoracic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Head & Neck 1

Conditions

Urinary Bladder Neoplasms 20Carcinoma, Renal Cell 12Colorectal Neoplasms 10Kidney Neoplasms 8Ovarian Neoplasms 6Neoplasms 5Carcinoma, Transitional Cell 5Urethral Neoplasms 4Stomach Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Urothelial Carcinoma of the Bladder 1

Interventions

pembrolizumab 7Nivolumab 4Carboplatin 4Taxes 3Paclitaxel 3Gene Expression Profiling 3rucaparib 2aflibercept 2Radiotherapy 2Polymerase Chain Reaction 2Leucovorin 2Irinotecan 2Interleukin-12 Subunit p35 2Fluorouracil 2Drug Therapy 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2veliparib 1trastuzumab deruxtecan 1tocilizumab 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1cc-486 1cabozantinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Fluorouracil × Genitourinary × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡